

# FULL YEAR 2018 RESULTS



**OLIVIER BRANDICOURT**

Chief Executive Officer, Sanofi

"In 2019 we will continue to build on the momentum achieved last year."


## Company sales & business EPS 2018

**€34,463M**  
+2.5% (-1.7%)  
SALES

**€5.47**  
+5.1% (-0.9%)  
BUSINESS EPS

Growth rates are expressed at constant exchange rates (CER). Growth rates in parentheses are expressed on a reported basis.

## Sales by global business unit



## Sales by geography



\*Eurasia: Russia, Ukraine, Georgia, Belarus, Armenia and Turkey

\*\*Rest of the World: Japan, South Korea, Canada, Australia, New Zealand and Puerto Rico.



**81**

**R&D highlights**

projects in development, including new molecular entities & additional indications



**35**

projects in Phase 3 or submitted for approval

For further information on Full Year 2018 Results and definitions of financial indicators, please refer to the press release issued on February 7, 2019, at:

[HTTPS://WWW.SANOFI.COM/EN/INVESTORS/](https://www.sanofi.com/en/investors/)

[SANOFI.COM](http://SANOFI.COM)



@Sanofi



Sanofi



@Sanofi

[SANOFI.US](http://SANOFI.US)



@SanofiUS



SanofiUS